What should be monitored when initiating or changing the dose of a RASi?
When initiating or changing the dose of a RASi, patients should be monitored for symptomatic hypotension, hyperkalemia, and serum creatinine within 2-4 weeks after, with the time interval depending on baseline BP, serum creatinine, and serum potassium. A shorter time interval is indicated if the baseline serum creatinine is high, or serum potassium is already high-normal, or there is a history of hyperkalemia or an acute rise in serum creatinine with BP lowering or RASi.